147269-61-2

Basic information

• Product Name: 3-Benzyloxycarbonylamino-6-methyl-2-pyridone
• Synonyms: 3-(Z)-Amino-6-methyl-2-pyridone;3-Benzyloxycarbonylamino-6-methyl-2-pyridone;3-Cbz-amino-6-methyl-2-pyridone;3-Cbz-amino-6-methyl-2-pyridone, 98+%;benzyl (6-methyl-2-oxo-1,2-dihydropyridin-3-yl)carbamate
• CAS NO: 147269-61-2
• Molecular Formula: C₁₄H₁₄N₂O₃
• Molecular Weight: 124.14052
• Mol File: 147269-61-2.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Benzyloxycarbonylamino-6-methyl-2-pyridone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzyloxycarbonylamino-6-methyl-2-pyridone(147269-61-2)
• EPA Substance Registry System: 3-Benzyloxycarbonylamino-6-methyl-2-pyridone(147269-61-2)

Safety Data

• Statements: R36/38:Irritating to eyes and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 147269-61-2(Hazardous Substances Data)

Upstream product

• 38116-61-9 2-hydroxy-6-methylnicotinic acid 
• 100-51-6 benzyl alcohol 
• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 
• 38116-61-9 6-Methylpyrid-2-one-3-carboxylic Acid 

Downstream Products

• 179524-33-5 2-[6-methyl-2-oxo-3-(benzyloxycarbonylamino)-2H-pyridin-1-yl]acetic acid t-butyl ester 
• 147269-62-3 ethyl (3-benzyloxycarbonylamino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 524948-02-5 3-Benzyloxycarbonylamino-1-[(2-methoxy-carbonyl)ethyl]-6-methyl-2-pyridinone 
• 147269-64-5 2-(3-benzyloxycarbonylamino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)-N-(3,3,3-trifluoro-2-hydroxy-1-isopropylpropyl)acetamide 
• 179524-35-7 t-butyl (3-benzylsufonylamino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 179523-60-5 [3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1,2-dihydropyridyl]acetic acid 
• 187163-89-9 2-(6-Methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-N-piperidin-4-ylmethyl-acetamide 

Relevant articles and documents

Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9and Het, R1, R7, R8, R12-R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Heteroaryl protease inhibitors and diagnostic imaging agents

Ketothiazole alkoxyguanidine and aminoguanidine analogs are described, including compounds of the Formula I: wherein X is O or NR9and Het, A, R1, R7, R8, R12, R13, Ra, Rb/s

ANTITHROMBOTIC AGENTS

Compounds of formula (I): Are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisa